These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32083454)

  • 1. Pridopidine in the treatment of Huntington's disease.
    Jabłońska M; Grzelakowska K; Wiśniewski B; Mazur E; Leis K; Gałązka P
    Rev Neurosci; 2020 May; 31(4):441-451. PubMed ID: 32083454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
    Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
    Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
    Squitieri F; de Yebenes JG
    Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
    Waters S; Tedroff J; Ponten H; Klamer D; Sonesson C; Waters N
    J Huntingtons Dis; 2018; 7(1):1-16. PubMed ID: 29480206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
    Kusko R; Dreymann J; Ross J; Cha Y; Escalante-Chong R; Garcia-Miralles M; Tan LJ; Burczynski ME; Zeskind B; Laifenfeld D; Pouladi M; Geva M; Grossman I; Hayden MR
    Mol Neurodegener; 2018 May; 13(1):25. PubMed ID: 29783994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
    Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
    J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacology of the dopaminergic stabilizer pridopidine.
    Ponten H; Kullingsjö J; Lagerkvist S; Martin P; Pettersson F; Sonesson C; Waters S; Waters N
    Eur J Pharmacol; 2010 Oct; 644(1-3):88-95. PubMed ID: 20667452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.
    Waters S; Ponten H; Edling M; Svanberg B; Klamer D; Waters N
    J Neural Transm (Vienna); 2014 Nov; 121(11):1337-47. PubMed ID: 24817271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins.
    Ruiz C; Casarejos MJ; Rubio I; Gines S; Puigdellivol M; Alberch J; Mena MA; de Yebenes JG
    Brain Res; 2012 Jun; 1459():100-12. PubMed ID: 22560595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats.
    Waters S; Ponten H; Klamer D; Waters N
    J Huntingtons Dis; 2014; 3(3):285-98. PubMed ID: 25300332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
    Ryskamp D; Wu J; Geva M; Kusko R; Grossman I; Hayden M; Bezprozvanny I
    Neurobiol Dis; 2017 Jan; 97(Pt A):46-59. PubMed ID: 27818324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.
    Francardo V; Geva M; Bez F; Denis Q; Steiner L; Hayden MR; Cenci MA
    Neurotherapeutics; 2019 Apr; 16(2):465-479. PubMed ID: 30756361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.
    Naia L; Ly P; Mota SI; Lopes C; Maranga C; Coelho P; Gershoni-Emek N; Ankarcrona M; Geva M; Hayden MR; Rego AC
    Neurotherapeutics; 2021 Apr; 18(2):1017-1038. PubMed ID: 33797036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.
    Sahlholm K; Sijbesma JW; Maas B; Kwizera C; Marcellino D; Ramakrishnan NK; Dierckx RA; Elsinga PH; van Waarde A
    Psychopharmacology (Berl); 2015 Sep; 232(18):3443-53. PubMed ID: 26159455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.
    Darpo B; Geva M; Ferber G; Goldberg YP; Cruz-Herranz A; Mehra M; Kovacs R; Hayden MR
    Neurol Ther; 2023 Apr; 12(2):597-617. PubMed ID: 36811812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
    Lundin A; Dietrichs E; Haghighi S; Göller ML; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
    Clin Neuropharmacol; 2010; 33(5):260-4. PubMed ID: 20616707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [
    Grachev ID; Meyer PM; Becker GA; Bronzel M; Marsteller D; Pastino G; Voges O; Rabinovich L; Knebel H; Zientek F; Rullmann M; Sattler B; Patt M; Gerhards T; Strauss M; Kluge A; Brust P; Savola JM; Gordon MF; Geva M; Hesse S; Barthel H; Hayden MR; Sabri O
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1103-1115. PubMed ID: 32995944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
    Geva M; Kusko R; Soares H; Fowler KD; Birnberg T; Barash S; -Wagner AM; Fine T; Lysaght A; Weiner B; Cha Y; Kolitz S; Towfic F; Orbach A; Laufer R; Zeskind B; Grossman I; Hayden MR
    Hum Mol Genet; 2016 Sep; 25(18):3975-3987. PubMed ID: 27466197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.